We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Australian Panel Urges New Pathways to Approve Medical Devices

Australian Panel Urges New Pathways to Approve Medical Devices

June 26, 2015

A panel of experts is calling on the Australian government to establish three new approval pathways for medium- and high-risk medical devices and align with the EU regulatory framework to expedite listing on the Australian Register of Therapeutic Goods.

The recommendations, announced last week, are tied to the government’s plan to fast-track approvals of promising new medical technologies and conduct joint reviews with trusted foreign regulators — part of a broad effort to streamline the country’s device approval process.

The Department of Health and Ageing launched an independent review of the current framework last October (IDDM, Nov. 3, 2014).

The first pathway calls for a conformity assessment by the Therapeutic Goods Administration or an organization designated by the TGA. Specific criteria would be established for conformity assessment bodies, including the capacity to set requirements for medical device classes.

The second pathway focuses on devices from overseas markets and would allow for approval by another national regulatory authority or an organization designated by that NRA.

The panel recommends that the government develop criteria for identifying comparable overseas designating authorities and NRAs to evaluate devices in consultation with consumers, health professionals, devicemakers and the TGA.

Under this pathway, the TGA would still have to determine a medical device has been correctly classified, its marketing approval documentation is in order and it meets Australian requirements to be included on the ARTG.

The third pathway would allow for expedited approval. In these cases, the TGA would be able to place conditions on the device’s inclusion in the ARTG.

Additionally, the report recommends that Class 1 nonsterile and nonmeasuring devices continue to be included on the ARTG based on a self-assessment by the manufacturer.

The TGA should make clear to consumers and healthcare providers that while those devices are registered, they haven’t been subject to independent assessment, the panel says.

Read the panel’s report, Review of Medicines and Medical Devices Regulation, here: www.fdanews.com/06-25-15-australiareport.pdf.
— John Bechtel

Regulatory Affairs

Upcoming Events

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

  • 12May

    Extractables and Leachables: 101

  • 19May

    CDRH’s New Accreditation Scheme for Conformity Assessment: Impacts on Your Future Testing Plans and FDA Submissions

  • 25May

    How Can the Accelerated Availability of Pfizer-BioNTech’s COVID-19 Vaccine be Replicated?

  • 27May

    Evolving Clinical Trials: Continuing the Journey from Paper to Digital

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Fujifilm_Logo.gif

    Fujifilm Begins Late-Stage Trial of Avigan for COVID-19

  • CE mark

    DiaSorin’s 10-Minute COVID-19 Antibody Test CE Marked

  • WHO

    WHO Will Review Two COVID-19 Vaccines from China

  • CE mark

    Qiagen’s High Throughput COVID-19 Test Earns CE Mark

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing